1193779-97-3

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-Chloro-2-methylphenyl)propan-1-one is used as an intermediate for the synthesis of various pharmaceuticals, contributing to the development of new medications and therapeutic agents.
Used in Organic Compounds Synthesis:
1-(5-Chloro-2-methylphenyl)propan-1-one serves as a key intermediate in the synthesis of a range of organic compounds, facilitating the creation of diverse chemical products.
Used in Agrochemicals Production:
1-(5-Chloro-2-methylphenyl)propan-1-one is utilized as an intermediate in the manufacture of agrochemicals, playing a role in the production of substances that help protect crops and enhance agricultural productivity.
Used in Fragrance Industry:
1-(5-Chloro-2-methylphenyl)propan-1-one is also employed as an intermediate in the production of fragrances, adding to the complexity and variety of scents used in the perfume, cosmetics, and personal care products.
Used in Specialty Chemicals:
1-(5-Chloro-2-methylphenyl)propan-1-one is used as a building block in the creation of specialty chemicals, which are tailored for specific applications and industries, highlighting its versatility in chemical synthesis.

Upstream product

• 7499-06-1 5-chloro-2-methylbenzoic acid 
• 925-90-6 ethylmagnesium bromide 
• 74-85-1 ethene 

Relevant academic research and scientific papers

Photoredox/nickel-catalyzed hydroacylation of ethylene with aromatic acids

We report a general, practical and scalable hydroacylation reaction of ethylene with aromatic carboxylic acids with the synergistic combination of nickel and photoredox catalysis. Under ambient temperature and pressure, feedstock chemicals such as ethylene can be converted into high-value-added aromatic ketones in moderate to good yields (up to 92%) with reaction time of 2-6 hours.

Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction

A series of bupropion (1a) analogues (1b-1ff) were synthesized, and their in vitro and in vivo pharmacological properties evaluated with the goal of developing a 1a analogue that had better properties for treating addictions. Their in vitro pharmacological properties were examined by [3H] dopamine ([3H]DA), [3H]serotonin ([3H]5HT), and [3H]norepinephrine ([3H]NE) uptake inhibition studies, and by binding studies at the dopamine, serotonin, and norepinephrine transporters using [125I]RTI-55 in cloned transporters. Several analogues showed increased [3H]DAuptake inhibition with reduced or little change in [3H]5HT and [3H]NE uptake inhibition relative to bupropion. Thirty-five analogues were evaluated in a 1 h locomotor activity observation test and 32 in an 8 h locomotor activity observation test and compared to the locomotor activity of cocaine. Twenty-four analogues were evaluated for generalization to cocaine drug discrimination after i.p. administration, and twelve analogues were tested in a time course cocaine discrimination study using oral administration. 2-(N-Cyclopropylamino)-3- chloropropiophenone (1x) had the most favorable in vitro efficacy and in vivo pharmacological profile for an indirect dopamine agonist pharmacotherapy for treating cocaine, methamphetamine, nicotine, and other drugs of abuse addiction. 2009 American Chemical Society.